Reversible protein phosphorylation is an essential regulatory mechanism in many cellular functions. In contrast to protein kinases, the role and regulation of protein phosphatases has remained ambiguous. To address this issue, we generated transgenic mice that overexpress the catalytic subunit ␣ of protein phosphatase 2A (PP2A) (PP2Ac␣) in the heart driven by the ␣-myosin heavy chain promoter. Overexpression of the PP2Ac␣ gene in the heart led to increased levels of the transgene both at RNA and protein levels. This was accompanied by a significant increase of PP2A enzyme activity in the myocardium. Morphological analysis revealed isles of necrosis and fibrosis. The phosphorylation state of phospholamban, troponin inhibitor, and eukaryotic elongation factor 2 was reduced significantly. The expression of junctional (calsequestrin) and free SR proteins (SERCA and phospholamban) was not altered. Whereas no increase in morbidity or mortality was noted, transgenic mice developed cardiac hypertrophy and reduced contractility of the heart, as well as cardiac dilatation as shown by biplane echocardiography. Taken together, these findings are indicative of the fundamental role of PP2A in cardiac function and imply that disturbances in protein phosphatases expression and activity may cause or aggravate the course of cardiac diseases.
Reversible protein phosphorylation is an essential regulatory mechanism in many cellular functions. In contrast to protein kinases, the role and regulation of protein phosphatases has remained ambiguous. To address this issue, we generated transgenic mice that overexpress the catalytic subunit ␣ of protein phosphatase 2A (PP2A) (PP2Ac␣) in the heart driven by the ␣-myosin heavy chain promoter. Overexpression of the PP2Ac␣ gene in the heart led to increased levels of the transgene both at RNA and protein levels. This was accompanied by a significant increase of PP2A enzyme activity in the myocardium. Morphological analysis revealed isles of necrosis and fibrosis. The phosphorylation state of phospholamban, troponin inhibitor, and eukaryotic elongation factor 2 was reduced significantly. The expression of junctional (calsequestrin) and free SR proteins (SERCA and phospholamban) was not altered. Whereas no increase in morbidity or mortality was noted, transgenic mice developed cardiac hypertrophy and reduced contractility of the heart, as well as cardiac dilatation as shown by biplane echocardiography. Taken together, these findings are indicative of the fundamental role of PP2A in cardiac function and imply that disturbances in protein phosphatases expression and activity may cause or aggravate the course of cardiac diseases.
Reversible protein phosphorylation is an essential regulatory mechanism in many cellular functions. Evidence has accumulated that, like protein kinases, protein phosphatases (PP) 1 are tightly and efficiently controlled in the cell and that abnormalities in PP function can cause or at least modify the course of diseases in human (1) . The main PP in the heart are serine/threonine phosphatases (reviewed in Ref. 2) . They are grouped mainly into PP 1, 2A, 2B, and 2C (3) . The main phosphatase activity in the heart is because of the catalytic subunits of PP1 and PP2A. More than a dozen PP1c (catalytic subunit of PP1) binding and regulatory proteins have been identified up to the present (2) . PP1c can bind to the cardiac RYR2 probably mediated via an additional protein, spinophilin (4) . Holoenzymes of PP2A contain a 36-kDa catalytic subunit (PP2Ac) and a regulatory subunit of 65 kDa termed PR65 (A subunit). A third subunit, B, can be associated with the core structure (5) . Molecular cloning revealed the existence of two mammalian PP2Ac isoforms ␣ and ␤, which share 97% identity in their primary sequence. Both isoforms are found in high levels in the heart. However, PP2Ac␣ is about 10 times more abundant than the PP2Ac␤ form, probably because of a more active gene promoter (reviewed in Ref. 1) . The isoforms are encoded by different genes. PP2A is remarkably constant during evolution and may even be the most conserved of all known proteins (1) . Overexpression in mammalian cells has hitherto been unsuccessful. Only inactive PP2Ac has recently been expressed in a baculovirus system (6) . A dominant negative mutant of PP2A␣, however, has been expressed in the brain of transgenic mice (7) . The B subunits confer subcellular localization, developmental regulation, and cell specificity to the PP2A holoenzyme (at least in brain). The A subunit is a structural subunit that is tightly associated with PP2Ac forming a scaffold to which the appropriate B subunit can bind (1, 2) .
␤-Adrenoreceptor stimulation leads to cAMP generation and to subsequent stimulation of cAMP-dependent protein kinases. The ␤-adrenoreceptor agonists increase the Ca 2ϩ release from the SR by stimulating the Ca 2ϩ influx through the L-type calcium channel. Relaxation of the muscle is because of the Ca 2ϩ pump in the SR, called SERCA. ␤-Adrenergic catecholamines enhance the activity of SERCA in an indirect way. Enhanced phosphorylation of phospholamban (PLB), an intrinsic membrane protein of the cardiac SR abolishes the inhibition of SERCA and more Ca 2ϩ is removed from the cytosol into the SR. During the next heartbeat more Ca 2ϩ can be released from the filled SR store and more force is generated. Hence PLB phosphorylation greatly contributes to the positive inotropic and relaxant effect of ␤-adrenergic stimulation in the heart (8) .
Increased phosphatase activity might contribute to cardiac hypertrophy and heart failure based on several independent lines of evidence. Increased mRNA expression and activity of PP1 has been noted in samples from patients suffering from end stage heart failure (9, 10). Increased phosphatase activity, if it is relevant, should lead to dephosphorylation of regulatory proteins, which has been reported by several independent laboratories: PLB (11, 12) and troponin (Tn) I (13, 14) are dephosphorylated in ventricles from patients with end stage heart failure. A causal link between heart failure and PP1 is further strengthened by an animal model. Chronic ␤-adrenergic stimulation by infusion of isoproterenol leads to cardiac hypertrophy, increased PP activity, and PLB dephosphorylation (15) . This is a clinically relevant model of heart dysfunction because increased ␤-adrenergic stimulation is a hallmark of human heart failure and many heart failure patients can be successfully treated with ␤-adrenoreceptor blockers. Cardiac specific overexpression of the catalytic subunit of PP1 in the mouse led to depressed cardiac function, dilated cardiomyopathy, and premature mortality consistent with heart failure (16) .
There is another line of evidence for a deleterious function of PP2A in the heart. Fostriecin, which is a somewhat selective PP2A inhibitor, can reduce the infarct size in rabbit hearts (17, 18) .
Based on these findings we hypothesized that increased expression of PP2A might, similarly as PP1c, alter cardiac function. We report here the generation of mice with cardiac specific overexpression of PP2A and followed the biochemical and physiological sequels to dissect the exact function of PPs in the mammalian heart.
EXPERIMENTAL PROCEDURES
Isolation of cDNA Encoding Mouse PP2Ac␣-Total RNA was extracted from mouse hearts using TriStar Reagent (AGS, Heidelberg, Germany) according to the manufacturers protocol. A 1382-bp fragment encompassing 69 bp of the 5Ј-untranslated region, the entire PP2Ac␣ coding region, and 326 bp of the 3Ј-untranslated region was generated using reverse transcription-polymerase chain reaction methodology (flanked with NotI and SalI sites). DNA sequence analysis was performed by an automated DNA sequencer (Model 310, Applied Biosystems, Weiterstadt, Germany).
Generation of Transgenic Mice-The NotI-SalI restriction enzyme fragment encoding mouse PP2Ac␣ along with its 5Ј-and 3Ј-untranslated regions was excised from the reverse transcriptase-PCR product and ligated into the same sites of a mouse cardiac ␣-myosin heavy chain promoter expression cassette containing the SV40 transcriptional terminator. The transgene, composed of the ␣-myosin heavy chain promoter, the entire protein coding region for mouse PP2Ac␣ (and 69 and 326 base pairs of 5Ј-and 3Ј-untranslated sequences, respectively), and the SV40 polyadenylation signal sequence was isolated from the parent plasmid as a 7-kilobase NruI fragment and used for microinjection of fertilized mouse eggs (CD1). Transgene-positive mice were identified by Southern blotting and PCR assay of tail genomic DNA. One founder lineage was established and used for further studies.
Northern Blot Analysis-Total RNA from mice hearts was isolated as described above. For purification of polyadenylated RNA from total RNA the Oligotex-mRNA Kit (Qiagen, Hilden, Germany) was used according to the manufacturers instructions. For Northern blot analysis 10 g of total RNA or 1 g of mRNA was separated by electrophoresis, transferred to nylon membranes, and hybridization was performed with EcoRI-EcoRV restriction fragments of the cDNA of mouse PP2Ac␣.
Preparation of Homogenates-Frozen tissue samples were pulverized in a mortar precooled in liquid nitrogen. The following steps were carried out at 4°C. Ten volumes of homogenization buffer containing (in mmol/liter) Tris-HCl (pH 7.4) 20; EDTA, 5; EGTA, 2; ␤-mercaptoethanol, 0.1% (v/v); phenylmethylsulfonyl fluoride, 0.5; and benzamidine, 1; were added to the frozen, pulverized tissue. The tissue was then homogenized three times for 30 s each with a Polytron PT-10 (Kinematica, Luzern, Switzerland). The homogenate was cleared by centrifugation for 10 min at 14,000 ϫ g. Protein was measured using the Bio-Rad protein assay (Bio-Rad).
Western Blot Analysis-For Western blot analysis, ventricular homogenates were prepared and 4ϫ strength SDS buffer containing 250 mmol/liter Tris-HCl (pH 6.8), 20% (w/v) SDS, 40% (v/v) glycerol, 1.2% (w/v) DL-dithiothreitol, and 0.004% (w/v) bromphenol blue was added. The samples were solubilized for 10 min at 95°C. Aliquots of 50 -200 g of protein were loaded per lane. Gels were run using 10% polyacrylamide separating gels. Proteins were electrophoretically transferred to nitrocellulose membranes (Protran, 0.45 M pore size, Schleicher and Schuell, Dassel, Germany) in 50 mmol/liter sodium phosphate buffer (pH 7.4) for 180 min at 1.5 Å at 4°C. Then, membranes were treated with Tris-buffered saline containing 5.0% nonfat dry milk powder and 0.05% Tween 20 for 120 min at room temperature or overnight at 4°C followed by incubation with antibodies directed against different proteins and subsequently with alkaline phosphatase-conjugated secondary antibodies (Sigma). Bands were detected using enhanced chemifluorescence (Amersham Biosciences). Fluorescent bands were visualized in a STORM PhosphorImager and quantified using the ImageQuaNT software (Amersham Biosciences). The following primary antibodies were used: polyclonal goat anti-PP2A catalytic subunit, polyclonal goat anti-PP2A regulatory subunit A␣ (both from Santa Cruz, Heidelberg, Germany), monoclonal mouse anti-PP2A regulatory subunit B56␣ (BD Transduction Laboratories, Heidelberg, Germany), polyclonal rabbit anti-␣4 (kindly provided by D. L. Brautigan, Charlottesville, VA), polyclonal rabbit anti-PP1␣ (BIOMOL, Hamburg, Germany), polyclonal rabbit anti-calsequestrin, polyclonal rabbit anti-SERCA2a (both kindly provided by L. R. Jones, Krannert Institute of Cardiology, Indianapolis, IN), monoclonal mouse anti-PLB (A-1, PhosphoProtein Research, Bardsey, UK), polyclonal rabbit anti-phospho-PLB (antibodies were raised against PLB-peptide phosphorylated at serine 16 or at threonine 17, PhosphoProtein Research, Bardsey, UK), monoclonal mouse anti-TnI (2F6.6) or anti-phospho-TnI (1E11.3) (kindly provided by G. S. Bodor, Denver Health Medical Center, Denver, CO), polyclonal rabbit anti-eEF2, and polyclonal rabbit anti-phospho(Thr 56 )-eEF2 (both from Cell Signaling Technology).
Protein Phosphatase Assay-Protein phosphatase activity was determined with a slight modification as described previously (19) with [ Immunocytochemical Procedures-For immunocytochemical analysis, routine paraffin sections of hearts of mice were mounted on polylysine-coated microslides (Menzel Glä ser, Braunschweig, Germany). For antigen retrieval, dewaxed and rehydrated tissue sections were immersed in 10 mmol/liter citric acid (pH 6.0), and boiled in a pressure cooker at an operating pressure of about 103 kPa/15 p.s.i. for 2 min. After cooling the slides were removed, quickly washed in running distilled water, and transferred to phosphate-buffered saline solution. Phosphate-buffered saline was used for all dilutions and washing steps. Subsequently, sections were encircled with a water-repellent PAP-pen (Dianova, Hamburg, Germany) and rinsed with phosphate-buffered saline. After blocking nonspecific binding sites (Fc receptors) with BSA-c basic blocking solution (1:10, Aurion, Wageningen, Netherlands), sections were immunoreacted overnight at 4°C with polyclonal goat primary antibodies recognizing the catalytic subunit of PP2A (Santa Cruz). Detection of bound primary antibodies was performed with fluorescein isothiocyanate-conjugated anti-goat IgG (Dianova, Hamburg, Germany). Finally, nuclei were counterstained for 15 s with 4,6-diamidino-2-phenylindole (5 g/ml phosphate-buffered saline; Sigma) and mounted with Vectashield (Vector Laboratories). The controls were omission of incubation with primary antibody and incubation in media containing the primary antibody that had been preincubated at room temperature for 2 h with a 10-fold molar excess of the corresponding control peptides.
Microscopy and Image Processing-Immunostained sections were examined on a Zeiss Axiophot2 microscope equipped with appropriate filters. Separate images for 4,6-diamidino-2-phenylindole staining, fluorescein isothiocyanate immunolabeling, and for autofluorescence of the myocardium and erythrocytes were captured digitally into colorseparated components using an AxioCam digital microscope camera and AxioVision multichannel image processing (Carl Zeiss Vision GmbH). The blue (for 4,6-diamidino-2-phenylindole), red (for autofluorescence), and green (for fluorescein isothiocyanate) components were merged, and composite images were imported as JPG files into PhotoImpact 3.0 (Ulead Systems, Inc., Torrance, CA) for analysis on Power PC followed with printing on a Hewlett-Packard DeskJet 970Cxi color printer. Images shown are representative of three independent experiments that gave similar results.
Echocardiography and Doppler Studies-Transthoracic echocardio-graphic measurements were performed on mice that were anesthetized intraperitoneally with a mixture of ketamine S (25 mg/kg) and xylazine (10 mg/kg) allowing spontaneous breathing. All measurements were made using a commercially available echocardiographic system (Philips Sonos 5500) equipped with a 15 MHz linear transducer for two-dimensional and M-mode imaging and a 12-MHz transducer for Doppler measurements. The parasternal long and short axes were obtained. Five heartbeats for every parameter were analyzed. The fractional shortening of the heart was calculated from the M-mode left ventricular diameters as (LVEDD-LVESD)/LVEDD ϫ 100, where LVEDD was the end-diastolic diameter and LVESD the end-systolic diameter. In addition, Doppler flow measurements of aortic and mitral flow were performed. The analysis of data was performed by two observers, who were blinded to the mouse lineage. Hemodynamic Performance-Left ventricular catheterization was performed in closed-chest mice anesthetized with tribromoethanol (15 l/g body weight of a 2.5% solution). Through the right carotid artery a 1.8 French size polyethylene catheter (Micromed, Houston, TX) was inserted into the left ventricle. Analog pressure signals were obtained using a pressure transducer TXD-310 (Micromed), recorded, and digitized at a sampling rate of 1,000 Hz with the PowerLab system (ADInstruments, Grand Junction, CO). The left jugular vein was cannulated for intravenous access. Increasing doses of the ␤-adrenoreceptor agonist dobutamine were administered via the left jugular vein using an automated syringe pump (B. Braun Melsungen). Heart rate, blood pressure, and the first derivative of left intraventricular pressure (ϩdP/dt and ϪdP/dt) were measured continuously.
Ca 2ϩ Transients and Shortening of Isolated Cardiomyocytes-Isolation of ventricular myocytes from PP2A transgenic and wild type mice, measurement of Ca 2ϩ transients, and measurement of cell shortening were performed as described previously (20) . The cells were incubated with the fluorescence dye Indo-1/AM and stimulated at 0.5 Hz. Excitation was at 365 nm, and the emitted fluorescence was recorded at 405 and 495 nm. The ratio of fluorescence at the two wavelengths was used as an index of cytosolic Ca 2ϩ concentration. Contractility of isolated cardiomyocytes was recorded with an edge detection system. The maximal magnitude of contraction was normalized to resting cell length and expressed as percent of shortening.
Whole Cell L-type Ca 2ϩ Current (I Ca )-Single cardiomyocytes were studied using the whole cell patch clamp technique as described previously (20) . Recordings were performed under conditions that suppress Na ϩ and K ϩ currents. Ca 2ϩ currents were elicited by voltage steps from a holding potential of Ϫ40 mV to a test potential of ϩ10 mV for 200 ms, applied every 10 s. Cell capacitance and I Ca were recorded with an L/M-PC amplifier (LIST-Electronic, Darmstadt, Germany) according to standard protocols.
Statistics-Data are presented as mean Ϯ S.E. Comparisons between groups were evaluated using Student's t test, with significance imparted at the p Ͻ 0.05 level.
RESULTS
Overexpression of PP2A Catalytic Subunit in the Heart of Transgenic Mice-The mouse cDNA encoding PP2Ac␣ was cloned from mouse hearts by reverse transcriptase-PCR and the sequence was confirmed by bidirectional sequencing. This cDNA was inserted into the expression cassette of an ␣-myosin heavy chain promoter containing vector. Standard procedures for generation of transgenic (TG) mice were used. One TG founder with germline transmission of the transgene was obtained.
PP2Ac expression in hearts from 10-week-old TG and wild type (WT) mice was studied by Northern and Western blotting. In Northern blots from both total RNA and mRNA we noted a clear detection of the transgene (Fig. 1, A and B) . Next, cardiac tissue was subjected to Western blotting to study protein expression. Here we also noted an elevation in PP2Ac␣ expression. This was quantified as a 2.1-fold increase (Fig. 1C and Table I ). The activity and localization of PP2Ac can be modified by different regulatory subunits. Therefore, we studied the expression of subunits A␣, B56␣ and ␣4, but no differences between TG and WT mice were observed in Western blotting (Fig. 1C and Table I ).
To clarify if the overexpressed PP2A was functionally active or not we determined the phosphatase activity in TG heart homogenates with phosphorylase a as substrate. We found an enhanced total phosphatase activity by 28% (Fig. 2) . To discriminate PP2A activity from PP1 activity we used 10 nM okadaic acid (OA), a concentration known to inhibit only PP2A but not PP1 (21) . On the assumption that the total activity was mainly based on PP1 and PP2A activity, PP2A activity was calculated as total activity minus activity in the presence of 10 nM OA. Whereas PP1 activity was unchanged between WT and TG mice, PP2A activity was enhanced 1.7-fold in TG homogenates. Therefore, the contribution of PP2A to the total protein phosphatase activity was shifted from 35% in WT hearts to 48% in TG hearts (Fig. 2) .
To visualize PP2Ac␣ expression in the myocardium, we carried out immunostaining of PP2Ac␣ in ventricular sections. Fig. 3A demonstrates localization and increased expression of PP2Ac␣ in cardiac myocytes of 10-week-old TG mice. We also used hematoxylin and eosin (Fig. 3B) , as well as elastica van Gieson (Fig. 3C) and Masson-Goldner trichrome (not shown) staining, and demonstrated isles of necrosis and indications of reactive fibrosis in the TG hearts. No such alterations were seen in littermate control hearts.
Expression and Phosphorylation of Regulatory Proteins in Hearts of PP2A-transgenic Mice-In contrast to PP2A, the expression of the catalytic subunit of PP1 remained unchanged (Table I) ϩ RNA (B), isolated from hearts of 10-week-old WT and PP2A-transgenic (TG) mice, revealed an increased expression of PP2Ac␣ mRNA in TG mice (upper panels). As control for equal RNA loading, the ethidium bromidestained gels are shown (lower panels). C, ventricular homogenates from 10-week-old WT and TG mice were subjected to Western blot analysis with specific antibodies (samples of 50 g (PP2A/A), 100 g (PP2A/B56␣ and ␣4), or 200 g (PP2A/C␣) were used). On the left, molecular mass markers in kDa are indicated. For the PP2A catalytic subunit a 2.1-fold increase in expression was detected compared with WT mice (Quantification, see Table I ). PP2A/A and PP2A/B56␣ and ␣4 expression remained unchanged. PP2A/C␣, catalytic subunit; PP2A/A, A subunit; and PP2A/B56␣, B56␣ regulatory subunit; ␣4, regulatory subunit. gation factor 2 (eEF-2), calsequestrin, sarcoplasmic reticulum Ca 2ϩ -ATPase (SERCA), PLB, and the inhibitory subunit of TnI remained unchanged in TG hearts (Fig. 4 and Table I ). Importantly, the phosphorylation state of the Ca 2ϩ regulatory proteins PLB and TnI as well as the phosphorylation state of eEF-2 was reduced in TG hearts. Analyses with phospho-specific antibodies revealed a decreased phosphorylation of TnI by 8.5%. A typical blot is depicted in Fig. 4B . The phosphorylation state of PLB at serine 16 and threonine 17, as detected by antibodies, was reduced by 7.9 and 12.9%, respectively, in TG ventricles ( Fig. 4A and Table I ). Moreover, the phosphorylation state of eEF-2 was reduced by 62% ( Fig. 4C and Table I) .
Hypertrophy, Dilatation, and Reduced Contractility of PP2A-transgenic Hearts-The absolute and relative heart weights were increased in 10-week-old TG mice by 29.5 and 23.4%, respectively (Table II) . This was accompanied by cellular hypertrophy (Table II) . As cardiac hypertrophy may affect heart function we studied the hemodynamic phenotype of the transgene overexpression. Cardiac catheterization revealed decreased pressure development in the left ventricle of 16-weekold TG mice (Table III) . In TG mice the maximal rate of left ventricular pressure development was decreased by 42%, and the maximal rate of pressure decline was decreased by 47% compared with WT hearts. To study the response to ␤-adrenergic stimulation, mice were stimulated by infusion of dobutamine, a ␤-adrenergic agonist. Whereas the positive chronotropic effect (Fig. 5A) was comparable, the maximal response in developed intraventricular pressure and its first derivative to ␤-adrenergic stimulation were blunted in TG mice (Fig. 5,  B-D) . With the highest dose of dobutamine applied (500 g/kg), the left ventricular pressure and its first derivative were elevated by 21.1 and 124% in TG animals compared with 45.6 and 235% in WT mice. Under noninvasive conditions, via doppler echocardiography, we also studied left ventricular diameters and performance. Here, we detected enhanced left ventricular enddiastolic (enlarged by 32%) and endsystolic (enlarged by 55%) diameters, indicative of dilated cardiomyopathy (Fig. 6 and Table IV) . Parameters of ventricular function were reduced as evidenced by a 31% decreased fractional shortening and a 25% decreased velocity of circumferential shortening for 16-week-old animals. To study the time course of the impaired ventricular function we performed cardiac ultrasound on mice at 8, 16, and 52 weeks of age. Cardiac dilatation was already present in 8-week-old mice. Whereas indices of impaired contractility were stationary between 8 and 16 weeks, fractional shortening and velocity of circumferential shortening were reduced by 26 and 17%, respectively, we noted a further deterioration of contractility at 52 weeks (Table IV) . The continuous dilatation of the left ventricle was more distinct between 8 and 16 weeks but proceeds up to 52 weeks of age, whereas no PLB-PS16, PLB phosphorylated at serine 16; PLB-PT17, PLB phosphorylated at threonine 17; TnI-P, phosphorylated TnI; P-eEF-2, phosphorylated eEF-2. Data are presented as mean Ϯ S.E. of n mice. 
FIG. 2.
Protein phosphatase activity in PP2A-transgenic mouse hearts. Ventricular homogenates from 10-week-old WT and PP2A-TG mice were prepared from frozen tissue samples. Aliquots containing 2.5 g of protein were preincubated with 10 nmol/liter okadaic acid (PP1 activity) or the corresponding amount of Me 2 SO (total activity) for 10 min and protein phosphatase activity was assayed using 32 P-labeled phosphorylase a as substrate. PP2A activity was calculated as the total activity Ϫ PP1 activity. Ordinate, phosphorylase phosphatase activity represented as differences were noted for WT mice during the whole time (Table IV) .
Calcium (Table V) .
DISCUSSION
Our previous work clearly showed that OA inhibits PP2A purified from animal and human heart (19, 22) . This was accompanied by an increase in PLB phosphorylation, TnI phosphorylation, and an increase in the peak current through the cardiac L-type Ca 2ϩ current (19) . In isolated electrically driven papillary muscles, OA increased force of contraction and hastened contraction, in a way very similar to isoproterenol (19) . These data strongly suggested an involvement of PP in cardiac force generation. Because OA inhibited several PP (PP2A as well as PP4 and PP5 in the nanomolar range, Ref. 23 ), it was difficult to correlate the cardiac effects of OA with inhibition of a specific PP. However, some evidence suggests that TnI dephosphorylation might occur through activity of PP2A (24). Here, we followed the opposite strategy: we generated a new model for the study of the biological role of PP in the heart by constitutively overexpressing the PP2Ac. This increased PP2A activity in the heart was accompanied by cardiac hypertrophy, by a depressed contractile function, and by dephosphorylation of PLB, TnI, and eEF-2.
Whereas forced PP2Ac overexpression in a transgenic animal model has not been reported until now a gene targeting approach clearly demonstrated that PP2A is necessary for normal development: mice lacking PP2Ac␣ suffer early fetal demise at embryonic day 6. PP2Ac␣ seems to be necessary for the onset of gastrulation and mesoderm formation (25) .
It is relevant in this context that an overexpressed isoform of a Ca 2ϩ -calmodulin kinase binds physically to PP2A (26) . In that work cardiac-specific overexpression of a nuclear ␦ B isoform of Ca 2ϩ -calmodulin kinase II led to cardiac hypertrophy and dilated cardiomyopathy in transgenic mice. In addition, the protein expression and the activity of PP2A were increased.
FIG. 4.
Reduced cardiac protein phosphorylation in PP2A-transgenic mice. Ventricular homogenates from 16-week-old WT and PP2A-TG mice were prepared. Samples of 100 g of protein were electrophoresed and subjected to Western blotting. A, blots were incubated with an antibody directed against PLB or with phosphorylationspecific antibodies directed against PLB phosphorylated at serine 16 (PLB-PS16) or threonine 17 (PLB-PT17). B, blots were incubated with an antibody directed against the inhibitory subunit of troponin (TnI) or with an antibody against phosphorylated TnI (TnI-P). C, blots were incubated with an antibody directed against the eEF-2 or with an antibody against phosphorylated eEF-2 (P-eEF-2). Molecular mass markers (in kDa) are indicated on the left side. Quantification of specific protein bands (Table I ) using the ImageQuaNT software showed a significant decrease in phosphorylation of PLB, TnI, and eEF-2 in TG mice compared with WT mice.
TABLE II
Cardiac hypertrophy in PP2A-transgenic mice Body weight, heart weight, and left ventricle (LV) weight from wild type (WT) and PP2A-TG mice were measured at 10 weeks of age. The diameter of cardiomyocytes was measured on photomicrographs of hematoxylin-eosin-stained sections through the ventricles from 16-weekold WT and TG mice. 100 cells from 3 animals of each group were examined. Data are presented as mean Ϯ S.E. of n mice. 
PP2A and Cardiac Dysfunction
The mechanism of how the nuclear ␦ B isoform of Ca 2ϩ -calmodulin kinase II leads to PP2A increase could not be resolved (26) . Apparently this increase was not transcriptionally mediated as the mRNA level of PP2A was not elevated (26) . Likewise the authors could not explain whether the increase in PP2A expression and activity was the cause of the cardiac hypertrophy and failure or whether the increase in PP2A activity was a compensatory mechanism against elevated kinase activity independent of the hypertrophy (26) .
What are possible mechanisms of PP2A-induced cardiac hypertrophy? PP2A can stimulate protein translation (and possibly hypertrophy) by dephosphorylation and hence activation of eEF-2. The mRNA translocation on the ribosome involves eEF-2. The eEF-2 is phosphorylated and inhibited by a specific kinase. Phosphorylation reduces the ability of the factor to promote translocation by decreasing its affinity for pretranslocation ribosomes (27, 28) . PP2A, the most potent phosphatase acting on eEF-2, dephosphorylates and therefore activates eEF-2 (29) . In rat neonatal cardiomyocytes angiotensin II, a well known hypertrophic stimulus, can lead to dephosphorylation of eEF-2 by PP2A activation (30) . Here we noted a dephosphorylation of eEF-2 in TG hearts. At least in parts an increased protein phosphatase activity in general may result in hypertrophy. Cardiac-specific overexpression of PP1 also resulted in depressed cardiac function and dilated cardiomyopathy (16) . An impaired Ca 2ϩ homeostasis was discussed as stimulus for cardiac hypertrophy and failure. Therefore, dephosphorylation of Ca 2ϩ regulatory proteins by PP1, PP2A, or another PP may be responsible for induction of hypertrophy. Regardless of this general mechanism by which PP2A can lead to hypertrophy, it will be important to elucidate the unique properties of PP2A. For instance, cross-breeding of PP2A-overexpressing mice with PP1-inhibitor-2-overexpressing mice revealed double transgenic mice with decreased total PP activity because of a nearly complete loss of PP1 activity. PP2A activity is still enhanced in these mice and they developed cardiac hypertrophy (31) .
PP2Ac␣ overexpression in the present paper was driven by the cardiac-specific and strong ␣-myosin heavy chain promoter. We detected a corresponding transcript (for PP2Ac␣) in Northern blots and a corresponding protein band in Western blots of TG hearts. As the catalytic subunit of PP2A is subject to a potent autoregulatory mechanism, which is exerted at the translational level, the difference between RNA and protein overexpression can be explained (32) . Only a massive RNA expression may overcome the tight control of PP2Ac expression. Moreover, cardiomyocyte specific localization of PP2Ac␣ was confirmed by immunohistology. It is interesting to note and may be the subject of subsequent work that PP2Ac␣ is present both in the cytosol and nucleus. Because of its nuclear localization, PP2A can be suggested to modulate gene transcription. Overexpressed PP2Ac␣ acts on regulatory proteins in the SR (PLB), in the contractile filaments (TnI), and on regulatory proteins in the SL (Ca 2ϩ channels). In the SR, PP2Ac␣ is part of a high molecular weight complex including the ryanodine receptor, FKBP12.6, PKA, PP1c, and the muscle A kinase anchor protein (33 and can reverse channel phosphorylation by protein muscle A kinase protein-anchored PKA (34) . The ␤ 2 -adrenergic receptor was found to be physically associated with the L-type Ca 2ϩ channel, a G protein, an adenylyl cyclase, PKA, and the counterbalancing PP2Ac in the brain (35) . Furthermore, previous studies have shown that intracellular addition of exogenous PP2A via pipette filling solution decreases basal L-type I Ca (36) . The use of calyculin A a potent PP1/PP2A inhibitor has revealed a major role in the regulation of steady-state L-type Ca 2ϩ channel activity in mouse cardiac myocytes. For instance I Ca density was increased after addition of calyculin A (37) . Although, a recent study supported the view that PP1 and PKC regulate the steady-state L-type Ca 2ϩ current, PP2A still reverses the effects of PKA (34, 35, 38) . Here, overexpression of PP2Ac␣ resulted in a decrease of I Ca density and a decelerated inactivation of the L-type Ca 2ϩ channels.
The increased PP2A activity detected in TG hearts was most likely the consequence of PP2Ac␣ overexpression, as the expression of the A-and B-subunit as well as ␣4, which can also alter PP2A activity, were found unchanged. Probably, unbound PP2Ac␣ may be increased in TG hearts. This should lead in part to an undirected PP activity. On the other hand the phosphorylation state of eEF-2 is much more decreased than the phosphorylation state of TnI or PLB. As the PKA expression is unchanged in TG mice, this argues for targeting of overexpressed PP2Ac␣ toward selected phosphoproteins, e.g. eEF-2. Possibly, not all regulatory subunits in WT mice are bound to a catalytic subunit and can function as a kind of spare proteins. Measured PP2A phosphatase activity using 32 P-labeled phosphorylase a as substrate was increased to a lower extent compared with the PP2Ac␣ protein expression. This observation may be explained by the binding of the murine ␣4 protein to PP2Ac␣. It was shown that ␣4 can bind directly to the catalytic subunit of PP2A with exclusion of other subunits. Moreover, binding of ␣4 alters the substrate specifity of PP2A, with an increase in activity toward myelin basic protein labeled by mitogen-activated protein kinase, relative to phosphorylase a (39) . This increased PP2Ac␣ activity should decrease the phosphorylation state and hence the function of, for instance, PLB or TnI, which was indeed the case. Furthermore, left ventricular pressure and its first derivative were lower in PP2Ac␣ overexpressing mice, indicating impaired function of cardiac regulatory proteins. PP2Ac␣ overexpression did not alter the protein levels of important regulatory proteins in the free and junctional SR-like PLB, SERCA, and calsequestrin. The maximal effect to ␤-adrenergic stimulation is lower in TG hearts compared with wild type. This may reflect additional functionally relevant structural abnormalities (such as the necrosis and fibrosis reported here) in the TG heart but not solely decreased protein phosphorylation. A reduced phosphorylation of PLB and TnI should be overcome by higher levels of ␤-adrenergic stimulation. For instance, reduced contractility was noted with PLB overexpression in the heart, but the contractile function was normalized by maximal stimulation with ␤-adrenoreceptor agonists (40, 41) . In summary, a novel model for studying the role of PP2A in the heart has been generated and characterized as leading to cardiac hypertro- phy and cardiac dilatation similar to some human forms of heart failure.
